LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation

Several preclinical studies demonstrate that antitumor efficacy of programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade can be improved by combination with other checkpoint inhibitors. Lymphocyte-activation gene 3 (LAG-3) is an inhibitory checkpoint receptor involved in T cell e...

Descripción completa

Detalles Bibliográficos
Autores principales: Sung, Eunsil, Ko, Minkyung, Won, Ju-young, Jo, Yunju, Park, Eunyoung, Kim, Hyunjoo, Choi, Eunji, Jung, Ui-jung, Jeon, Jaehyoung, Kim, Youngkwang, Ahn, Hyejin, Choi, Da-som, Choi, Seunghyun, Hong, Youngeun, Park, Hyeyoung, Lee, Hanbyul, Son, Yong-Gyu, Park, Kyeongsu, Won, Jonghwa, Oh, Soo Jin, Lee, Seonmin, Kim, Kyu-pyo, Yoo, Changhoon, Song, Hyun Kyu, Jin, Hyung-seung, Jung, Jaeho, Park, Yoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372323/
https://www.ncbi.nlm.nih.gov/pubmed/35526096
http://dx.doi.org/10.1016/j.ymthe.2022.05.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372323/
https://www.ncbi.nlm.nih.gov/pubmed/35526096
http://dx.doi.org/10.1016/j.ymthe.2022.05.003

Ejemplares similares